News and Trends 25 Aug 2022 Evotec SE acquires highly-flexible drug manufacturing space for €1 A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Clearance given to clinical trial with potential to change course of brain disease A trial to look at gene therapy, BV-01, for Huntington’s Disease has been given the go ahead to take place in France and has ‘the potential to change the course of the devastating disease. Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, received clearance for the phase 1/2 […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Vocal biomarker agreement set to benefit patients with COPD in India A new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India is being developed after a multi-year agreement was signed. The agreement between Sonde Health, a vocal biomarker company, and Koye Pharmaceuticals, a pharma organization, was signed today (August 24). The deal represents Sonde’s first partnership with a pharmaceutical company. Develop […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Hera Biotech bags $1.9M for endometriosis diagnostic test San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Study findings could lead to new anti-cancer drugs German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system. Many tumor cells mist themselves with a protective ‘perfume’ that disables the immune system. But a drug already approved for other purposes can apparently render this weapon harmless. This is the conclusion of a […] August 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Millions in funding and new board members for Belgian mRNA company The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences LLC with participation from Professor Kenneth Chien, […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 24 Aug 2022 COVID-19 vaccine less sensitive to mutations being developed in Sweden A new generation of coronavirus vaccine is being developed by Swedish researchers from the Karolinska Institutet. The vaccine is being specifically designed to be less sensitive to mutations and better equipped for any future strains. Promising results The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Potential new treatment for angioimmunoblastic T-cell lymphoma? A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 24 Aug 2022 To reach Mars, we need biotechnology As we prepare for long-distance space travel and life on Mars, biotechnology will be essential to make spaceships no longer dependent on Earth’s constant supply. “As human beings, we need a constant supply of oxygen. We need constant access to nutritious food, clean water and a safe and clean waste disposal system,” says Italian astronaut […] August 24, 2022 - 11 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 BioAge partners with Age Labs to study healthy life length BioAge Labs, Inc., a biotech company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, has partnered with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Oncolyze seeking investment for AML clinical trials After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […] August 24, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email